Paper
0
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Authors
Published
Oct 15, 2014
Show more
Save
Tip0
TipSave
Abstract
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.